Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Incyte Corp (NQ: INCY )

70.39 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corp

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
Don't overlook NASDAQ:INCY—a stock with solid growth prospects and a reasonable valuation.
In the world of growth stocks, NASDAQ:INCY shines as a value proposition. 
Via Chartmill
Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends
Incyte acquires Escient Pharmaceuticals for $750 million, bolstering its pipeline. Cantor Fitzgerald initiates coverage with a Neutral rating, citing undervaluation concerns despite strong cash flow. 
Via Benzinga
Peeling Back The Layers: Exploring Incyte Through Analyst Insights
Via Benzinga
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
From Incyte and Escient Pharmaceuticals
Via Business Wire
NASDAQ:INCY stands out as a growth opportunity that won't break the bank.
NASDAQ:INCY is showing good growth, while it is not too expensive. 
Via Chartmill
NASDAQ:INCY, a growth stock which is not overvalued.
Despite its growth, NASDAQ:INCY remains within the realm of affordability. 
Via Chartmill
When you look at NASDAQ:INCY, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Don't overlook INCYTE CORP (NASDAQ:INCY)—it's a hidden gem with strong fundamentals and an attractive price tag. 
Via Chartmill
Incyte to Report First Quarter Financial Results
From Incyte
Via Business Wire
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates... 
Via Talk Markets
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
From Incyte
Via Business Wire
Incyte Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
Via Benzinga
NASDAQ:INCY stands out as a stock that provides good value for the fundamentals it showcases.
INCYTE CORP (NASDAQ:INCY): good value for what you're paying. 
Via Chartmill
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
For those who appreciate value investing, NASDAQ:INCY is a compelling option with its solid fundamentals.
INCYTE CORP (NASDAQ:INCY) is an undervalued gem with solid fundamentals. 
Via Chartmill
Penny Stock Detox: 3 Stocks to Buy for Multibagger Returns Instead
Don't fall for the siren song of penny stocks. Rather, fill your portfolio with companies that have a proven track record of success. 
Via InvestorPlace
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
From Incyte Corporation
Via Business Wire
The Analyst Verdict: Incyte In The Eyes Of 8 Experts
Via Benzinga
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
From Incyte
Via Business Wire
3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise
Discover the pivotal roles of cancer-fighting biotech stocks that are advancing cancer research and subsequently, their financial growth. 
Via InvestorPlace
New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
From Incyte
Via Business Wire
Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI
From Incyte
Via Business Wire
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
From Incyte
Via Business Wire
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off. 
Via InvestorPlace
NASDAQ:INCY stands out as a growth opportunity that won't break the bank.
For those who appreciate growth without the sticker shock, INCYTE CORP (NASDAQ:INCY) is worth considering. 
Via Chartmill
Exit Now! 3 Biotech Stocks to Sell in February 2024
These biotech stocks to sell represent incredibly risky bets, amidst the sector's volatility and looming economic unpredictability. 
Via InvestorPlace
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
From Incyte
Via Business Wire
Despite its impressive fundamentals, NASDAQ:INCY remains undervalued.
INCYTE CORP (NASDAQ:INCY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
Earnings Scheduled For February 13, 2024
Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.